Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma

Acta Dermato-Venereologica

Volumn 96, Issue 2, 2016, Pages 259-260

  Matsumura, Natsuko ^a   Ohtsuka, Mikio ^a   Kikuchi, Nobuyuki ^a   Yamamoto, Toshiyuki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; COLECALCIFEROL; DACARBAZINE; NIMUSTINE; NIVOLUMAB; PREDNISOLONE; SULTAMICILLIN; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; EPILUMINESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG INFILTRATE; MALE; METASTATIC MELANOMA; PRIORITY JOURNAL; PSORIASIS; RECURRENT DISEASE; SKIN BIOPSY; SKIN EXAMINATION; THORAX RADIOGRAPHY; VERY ELDERLY; BIOPSY; CHEMICALLY INDUCED; DISEASE COURSE; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MELANOMA; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; DISEASE PROGRESSION; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MELANOMA; PSORIASIS; SKIN NEOPLASMS;

EID: 84954554294     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2212     Document Type: Article

References (6)

1. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 2014; 71: 141-150.
2. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011; 350: 17-37.
3. Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen- Engels LJ, Hobo W, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 2012; 35: 169-178.
4. Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2011; 17: 896-906.
5. Ohtsuka M, Miura T, Mori T, Yamamoto T. Occurrence of psoriasiform eruption during nivolumab therapy for a patient with primary oral mucosal melanoma. JAMA Dermatology 2015; 151: 797-799.
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.